Back to the list
Congress: ECR25
Poster Number: C-27030
Type: Poster: EPOS Radiologist (scientific)
Authorblock: Y. Yang, H. Huang, Z. Wen; Beijing/CN
Disclosures:
Yuming Yang: Nothing to disclose
Hao Huang: Nothing to disclose
Zhiyong Wen: Nothing to disclose
Keywords: Genital / Reproductive system male, Oncology, Pelvis, MR, Computer Applications-Detection, diagnosis, Diagnostic procedure, Cancer, Neoplasia
References
  1. Schoots IG, Barentsz JO, Bittencourt LK, et al. PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. AJR Am J Roentgenol. 2021;216(1):3-19. doi:10.2214/AJR.20.24268
  2. Schieda N, Krishna S, Davenport MS. Update on Gadolinium-Based Contrast Agent-Enhanced Imaging in the Genitourinary System. AJR Am J Roentgenol. 2019;212(6):1223-1233.
  3. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340-351.
  4. Porter KK, King A, Galgano SJ, Sherrer RL, Gordetsky JB, Rais-Bahrami S. Financial implications of biparametric prostate MRI. Prostate Cancer Prostatic Dis. 2020;23(1):88-93.
  5. Zheng Y, Li W, Zhang Y, Zhang C, Wang J, Ge P. Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4-20 ng/mL. Sci Rep. 2022;12(1):21895.
  6. Roobol MJ, van Vugt HA, Loeb S, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61(3):577-583.
  7. Wu YS, Zhang N, Liu SH, et al. The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study. Asian J Androl. 2016;18(6):925-929.
  8. Gan JM, Kikano EG, Smith DA, et al. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI. AJR Am J Roentgenol. 2022;218(5):859-866.
  9. Wallström J, Geterud K, Kohestani K, et al. Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial. Eur Radiol. 2021;31(11):8692-8702.
  10. Huang Y, Li ZZ, Huang YL, Song HJ, Wang YJ. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis. Medicine (Baltimore). 2018;97(13):e0249.
  11. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(5):479-505.
  12. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244-252.
  13. Steyerberg EW, Harrell FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54(8):774-781.
GALLERY